WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 7'3901 Infant (under 12 months) mortality rate: 132
GDP / capita (US$): 10'9911 Child (under 5 years) mortality rate: 142

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 178  177  176  176  175  157  138  118 
Births
Surviving infants
Pop. less than 5 years 11  11  11  11  11  16  18  17 
Pop. less than 15 years 34  35  36  37  38  51  50  52 
Female 15-49 years 50  50  50  50  50  41  33  26 

Number of reported cases

(Click for retrospective incidence data for Saint Lucia)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  30  35 
Mumps
ChartChart
 
Pertussis
ChartChart
  19 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Saint Lucia)
Vaccine year result method % card seen                                                
BCG          96  99*  89  99*  99*  91  94  27 
DTP1          95  99*  99*  99*  99*  76 
DTP3          95  99*  99  99*  98  70  89  56 
DTP4          90  83  85 
IPV1          95  21 
HepB_BD         
HepB3          99*  99  99*  98 
Hib3          99*  99  99*  98 
JapEnc         
MCV1          99*  97  99*  99*  99*  88  82 
MCV2          88  95  79  62  80  89 
MenA         
PCV1         
PCV2         
PCV3         
Pol3          95  99*  99  99*  98  70  90  58 
Rota1         
RotaC         
RCV1          97  99*  99*  99* 
TT2plus          16 
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Saint Lucia)
BCG
ChartChart
  96  99  89  99  99  91  94  27 
DTP1
ChartChart
  95  99  99  99  99  76  96  79 
DTP3
ChartChart
  95  99  99  99  98  70  89  56 
HepB3
ChartChart
  95  99  99  99  98 
HepB_BD
ChartChart
 
Hib3
ChartChart
  95  99  99  99  98 
IPV1
  95  21 
MCV1
ChartChart
  99  97  99  99  99  88  82 
MCV2
ChartChart
  88  95  79  62  80  89 
PCV3
 
Pol3
ChartChart
  95  99  99  99  98  70  90  58 
RCV1
ChartChart
  99  97  99  99  99  88  82 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 56
From 80 to 89% 22
From 50 to 79% 22
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG 2 months; Yes
DT > 6 years; Yes
DTwP 18 months; 5 years Yes
DTwPHibHepB 2, 4, 6 months; Yes
HepB_Adult Yes adolescents and adults
HepB_Pediatric birth; Yes
Influenza_Adult Yes chronic diseases, pregnant women, health care workers, and toher risk groups
IPV 2 months; Yes
MMR 12, 18 months; Yes
OPV 4, 6, 18 months; 5, 11-12 years; Yes
Pneumo_conj 2, 4, 6, 18 months; Yes infants with chronic illness
Td 11-12 years; Yes
Varicella Yes High risk
YF Yes Travelers

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  Yes  Yes  Yes  Yes 
What years does the MYP cover? number NA      2014-2015  2013-2014  2012-2013  2011-2012 
Nº of districts with microplans that include activities to raise immunization coverage number 36 

System performance

Total Nº districts in country number 36  36 
Nº districts with DTP3 coverage >=80% number 27  31 
% of districts with DTP3 coverage >=80% From 0 to 100% 78  100  75  86  100  89  78 
Nº districts with measles (MCV1) coverage >=95% number 20  19 
% of districts with MCV1 coverage >=95% From 0 to 100% 56  44  56  53  33  22  33 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  No  No  No  No 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 98  87  91  99  93  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  No  No  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.